Opposite effects of arsenic trioxide on the Nrf2 pathway in oral squamous cell carcinoma in vitro and in vivo

Cancer Letters

Volumn 318, Issue 1, 2012, Pages 93-98

  Zhang, Xinyan ^a   Su, Ying ^a   Zhang, Min ^a   Sun, Zheng ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Arsenic trioxide; Nrf2; Oral squamous cell carcinoma

Indexed keywords

ARSENIC TRIOXIDE; TRANSCRIPTION FACTOR NRF2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLONY FORMATION; CONTROLLED STUDY; DRUG MECHANISM; GENE; HEME OXYGENASE 1 GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MOUTH CARCINOMA; NONHUMAN; NQO1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; ENDOTHELIUM, VASCULAR; HEME OXYGENASE-1; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, NUDE; MOUTH NEOPLASMS; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; OXIDES;

EID: 84857139744     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.12.005     Document Type: Article

References (27)

1. Itoh K., Tong K.I., Yamamoto M. Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free Radical Biol. Med. 2004, 36:1208-1213.
2. Baird L., Dinkova-Kostova A.T. The cytoprotective role of the Keap1-Nrf2 pathway. Arch. Toxicol. 2011, 85:241-272.
3. Surh Y.J., Kundu J.K., Na H.K. Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med. 2008, 74:1526-1539.
4. Saw C.L., Kong A.N. Nuclear factor-erythroid 2-related factor 2 as a chemopreventive target in colorectal cancer. Expert. Opin. Ther. Targets 2011, 15:281-295.
5. Lau A., Villeneuve N.F., Sun Z., Wong P.K., Zhang D.D. Dual roles of Nrf2 in cancer. Pharmacol. Res. 2008, 58:262-270.
6. Ruthworth S.A., MacEwan D.J. The role of Nrf2 and cytopretective in regulating chemotherapy resistance of human leukemia cells. Cancers 2011, 3:1605-1621.
7. Kensler T.W., Wakabayashi N. Nrf2: friend or foe for chemoprevention. Carcinogenesis 2010, 31:90-99.
8. Hayakawa F., Privalsky M.L. Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell 2004, 5:389-401.
9. Antman K.H. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 2001, 6(Suppl. 2):1-2.
10. Kumar P., Gao Q., Ning Y., et al. Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone. Mol. Cancer Ther. 2008, 7:2060-2069.
11. Tsai C.W., Chang N.W., Tsai R.Y., et al. Synergistic cytotoxic effects of arsenic trioxide plus dithiothreitol on mice oral cancer cells. Anticancer Res. 2010, 30:3655-3660.
12. Su C.C., Lin Y.Y., Chang T.K., et al. Incidence of oral cancer in relation to nickel and arsenic concentrations in farm soils of patients' residential areas in Taiwan. BMC Public Health 2010, 10:67-76.
13. Pi J., Diwan B.A., Sun Y., et al. Arsenic-induced malignant transformation of human keratinocytes: involvement of Nrf2. Free Radical Biol. Med. 2008, 45:651-658.
14. Zhao C.Q., Young M.R., Diwan B.A., Coogan T.P., Waalkes M.P. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc. Natl. Acad. Sci. USA 1997, 94:10907-10912.
15. Bode A.M., Dong Z. The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit. Rev. Oncol. Hematol. 2002, 42:5-24.
16. Bornstein J., Sagi S., Haj A., Harroch J., Fares F. Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line. Gynecol. Oncol. 2005, 99:726-729.
17. Zhang X.W., Yan X.J., Zhou Z.R., et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010, 328:240-243.
18. Zhang X., Yang F., Shim J.Y., et al. Identification of arsenic-binding proteins in human breast cancer cells. Cancer Lett. 2007, 255:95-106.
19. Morales A.A., Gutman D., Cejas P.J., Lee K.P., Boise L.H. Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis. J. Biol. Chem. 2009, 284:12886-12895.
20. He X., Chen M.G., Lin G.X., Ma Q. Arsenic induces NAD(P)H-quinone oxidoreductase I by disrupting the Nrf2 x Keap1 x Cul3 complex and recruiting Nrf2 x Maf to the antioxidant response element enhancer. J. Biol. Chem. 2006, 281:23620-23631.
21. Massrieh W., Derjuga A., Blank V. Induction of endogenous Nrf2/small maf heterodimers by arsenic-mediated stress in placental choriocarcinoma cells. Antioxid. Redox Signal. 2006, 8:53-59.
22. Wang X.J., Sun Z., Chen W., et al. Activation of Nrf2 by arsenite and monomethylarsonous acid is independent of Keap1-C151: enhanced Keap1-Cul3 interaction. Toxicol. Appl. Pharmacol. 2008, 230:383-389.
23. Sekhar K.R., Rachakonda G., Freeman M.L. Cysteine-based regulation of the CUL3 adaptor protein Keap1. Toxicol. Appl. Pharmacol. 2010, 244:21-26.
24. He X., Ma Q. NRF2 cysteine residues are critical for oxidant/electrophile-sensing, Kelch-like ECH-associated protein-1-dependent ubiquitination-proteasomal degradation, and transcription activation. Mol. Pharmacol. 2009, 76:1265-1278.
25. He X., Ma Q. Critical cysteine residues of Kelch-like ECH-associated protein 1 in arsenic sensing and suppression of nuclear factor erythroid 2-related factor 2. J. Pharmacol. Exp. Ther. 2010, 332:66-75.
26. Subbarayan P.R., Lee K., Ardalan B. Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU. Anticancer Res. 2010, 30:1157-1162.
27. Tomuleasa C., Soritau O., Fischer-Fodor E., et al. Arsenic trioxide plus cisplatin/interferon alpha-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma. Hematol. Oncol. Stem Cell Ther. 2011, 4:60-66.